Regulatory & Policy Updates

SHERIDAN, WYOMING - December 8, 2025 - The CDC's Advisory Committee on Immunization Practices (ACIP) has triggered a major shift in U.S. newborn immunization policy, voting 8-3 to delay the hepatitis B vaccine for infants born to hepatitis B-negative mothers from the traditional birth dose to two months of age, despite decades of evidence and CDC messaging that the shot is safe, effective and critical for long-term protection.

A Narrow Vote to Delay the Birth Dose for Some Newborns

Under the new recommendation, only babies born to mothers who test positive for hepatitis B-or whose status is unknown-would still receive the birth dose. For infants of mothers who test negative, the vaccine can be delayed until two months, effectively dismantling the universal birth-dose strategy that has been in place for about 30 years.

SHERIDAN, WYOMING - December 4, 2025 - Butler National Corporation's Avcon Industries has secured European Union Aviation Safety Agency (EASA) and UK Civil Aviation Authority (CAA) approvals for its non-halon portable fire extinguisher retrofit on Learjet cabins, giving operators a certified, drop-in path to meet the looming December 31, 2025 halon phase-out deadline. The new approvals extend an earlier FAA Supplemental Type Certificate (STC) and position Avcon as a one-stop regulatory solution provider for Learjet fleets operating across North America, the UK and Europe.

Halon Phase-Out Drives Urgent Retrofit Decisions

SHERIDAN, WYOMING - December 2, 2025 - A leaked memo from FDA vaccine chief Vinay Prasad alleging that COVID-19 vaccines caused the deaths of 10 children has triggered a sharp backlash from scientific experts and investors, underscoring deep tensions inside U.S. vaccine regulation and adding fresh volatility for mRNA players Moderna and BioNTech.

An internal memo with external market consequences

In a six-page document titled "Deaths in children due to COVID-19 vaccines and CBER's path forward," Center for Biologics Evaluation and Research head Vinay Prasad claimed that an internal investigation had identified 10 child deaths "linked" to COVID-19 vaccination, based on reports in the Vaccine Adverse Events Reporting System (VAERS). The memo, published by The Washington Post, did not provide specific data, case details or manufacturer names.

SHERIDAN, WYOMING - December 2, 2025 - Imvax is moving its autologous glioblastoma immunotherapy IGV-001 toward the FDA, despite a missed primary endpoint in Phase IIb, betting that a six-month overall survival benefit and a novel "synergistic" treatment concept will resonate in a setting where outcomes have barely budged in two decades.

Phase IIb data highlight survival benefit despite PFS miss

In a mid-stage trial of 99 patients with newly diagnosed glioblastoma, Imvax evaluated IGV-001, a biologic-device combination, against placebo. While the study did not achieve its primary endpoint of improving progression-free survival, the company reported a median overall survival of 20.3 months in the treatment arm-around six months longer than in the control group.

SHERIDAN, WYOMING - December 2, 2025 - A series of FDA findings at Novo Nordisk's Bloomington, Indiana, fill/finish facility is forcing biotechs to rethink their commercial manufacturing strategies, with Regeneron and Scholar Rock now accelerating alternative capacity plans to break regulatory logjams linked to the ex-Catalent site.

FDA scrutiny at Novo's Bloomington site triggers CRLs

The Bloomington plant, one of three former Catalent sites Novo acquired for $11 billion to support surging GLP-1 demand, has become a bottleneck rather than a release valve for some of its biopharma customers. As a CDMO hub, the facility provided fill/finish services for a range of partners, but repeated quality issues have resulted in an Official Action Indicated (OAI) classification and multiple complete response letters (CRLs) from the FDA.

SHERIDAN, WYOMING - December 2, 2025 - As the United States grapples with record-setting government shutdowns and budget fights, the country's biotech and research ecosystem is confronting a deeper structural problem: federal science funding is increasingly unstable, putting early-stage innovation, talent pipelines and long-term competitiveness at risk. For an industry built on long horizons and high-risk discovery, interruptions to programs such as NIH grants and Small Business Innovation Research (SBIR) contracts are more than a temporary setback-they threaten the foundations of America's leadership in biopharma innovation.

Federal science funding as the backbone of U.S. biopharma

SHERIDAN, WYOMING - November 25, 2025 - Philips has received U.S. FDA 510(k) clearance for the latest release of its Cardiovascular Workspace (IntelliSpace Cardiovascular, ISCV), enabling U.S. health systems to deploy the cardiovascular imaging and information management platform as a cloud-hosted, SaaS solution on Philips HealthSuite. The move positions hospitals and cardiology networks to modernize IT, scale integrated diagnostics, and accelerate real-world adoption of AI-enabled cardiovascular workflows.

Cloud-based cardiovascular informatics for U.S. health systems